Harmony Biosciences Holdings Stock Working Capital

HRMY Stock

USD 34.67 1.08 3.02%

Harmony Biosciences Holdings fundamentals help investors to digest information that contributes to Harmony Biosciences' financial success or failures. It also enables traders to predict the movement of Harmony Stock. The fundamental analysis module provides a way to measure Harmony Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Harmony Biosciences stock.

	Last Reported	Projected for Next Year
Net Working Capital	287.3 M	194.1 M
Change In Working Capital	35 M	36.8 M

Change In Working Capital is likely to rise to about 36.8 M in 2024, whereas Net Working Capital is likely to drop slightly above 194.1 M in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Harmony Biosciences Holdings Company Working Capital Analysis

Harmony Biosciences' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Harmony Biosciences Working Capital

287.29 M

Most of Harmony Biosciences' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Harmony Biosciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Harmony Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Harmony Biosciences is extremely important. It helps to project a fair market value of Harmony Stock properly, considering its historical fundamentals such as Working Capital. Since Harmony Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Harmony Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Harmony Biosciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Long Term Debt	Intangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Current Deferred Revenue	Short Long Term Debt	Short Term Debt
Total Assets		0.87	0.91	-0.12	0.02	0.66	0.93	0.95	0.99	-0.92	0.94	-0.51	-0.98	0.91	0.9	-0.61	0.9	-0.51	0.88	0.63	0.63
Total Stockholder Equity	0.87		0.96	-0.41	0.42	0.8	0.71	0.92	0.87	-0.8	0.88	-0.78	-0.83	0.76	0.74	-0.85	0.93	-0.78	0.91	0.82	0.82
Net Tangible Assets	0.91	0.96		-0.42	0.26	0.67	0.79	0.96	0.94	-0.92	0.94	-0.68	-0.87	0.87	0.86	-0.76	0.88	-0.68	0.84	0.71	0.71
Net Debt	-0.12	-0.41	-0.42		-0.77	-0.21	0.13	-0.19	-0.2	0.16	-0.26	0.38	-0.04	-0.01	0.0	0.37	-0.3	0.38	-0.27	-0.41	-0.41
Retained Earnings	0.02	0.42	0.26	-0.77		0.41	-0.28	0.04	0.04	0.14	0.11	-0.48	0.13	-0.25	-0.26	-0.45	0.36	-0.48	0.42	0.51	0.51
Accounts Payable	0.66	0.8	0.67	-0.21	0.41		0.61	0.7	0.6	-0.53	0.5	-0.92	-0.64	0.52	0.49	-0.93	0.84	-0.92	0.75	0.97	0.97
Total Liab	0.93	0.71	0.79	0.13	-0.28	0.61		0.91	0.9	-0.92	0.79	-0.47	-0.97	0.95	0.95	-0.55	0.75	-0.47	0.69	0.55	0.55
Net Invested Capital	0.95	0.92	0.96	-0.19	0.04	0.7	0.91		0.96	-0.97	0.92	-0.66	-0.96	0.95	0.94	-0.75	0.87	-0.66	0.81	0.7	0.7
Total Current Assets	0.99	0.87	0.94	-0.2	0.04	0.6	0.9	0.96		-0.94	0.96	-0.49	-0.96	0.91	0.91	-0.59	0.88	-0.49	0.86	0.6	0.6
Capital Stock	-0.92	-0.8	-0.92	0.16	0.14	-0.53	-0.92	-0.97	-0.94		-0.89	0.52	0.93	-0.99	-0.98	0.61	-0.75	0.52	-0.67	-0.55	-0.55
Net Working Capital	0.94	0.88	0.94	-0.26	0.11	0.5	0.79	0.92	0.96	-0.89		-0.42	-0.91	0.85	0.84	-0.54	0.85	-0.42	0.85	0.51	0.51
Common Stock	-0.51	-0.78	-0.68	0.38	-0.48	-0.92	-0.47	-0.66	-0.49	0.52	-0.42		0.51	-0.49	-0.46	0.99	-0.72	1.0	-0.59	-0.95	-0.95
Property Plant Equipment	-0.98	-0.83	-0.87	-0.04	0.13	-0.64	-0.97	-0.96	-0.96	0.93	-0.91	0.51		-0.95	-0.94	0.61	-0.85	0.51	-0.81	-0.59	-0.59
Long Term Debt	0.91	0.76	0.87	-0.01	-0.25	0.52	0.95	0.95	0.91	-0.99	0.85	-0.49	-0.95		0.99	-0.58	0.71	-0.49	0.63	0.51	0.51
Intangible Assets	0.9	0.74	0.86	0.0	-0.26	0.49	0.95	0.94	0.91	-0.98	0.84	-0.46	-0.94	0.99		-0.55	0.68	-0.46	0.63	0.47	0.47
Long Term Debt Total	-0.61	-0.85	-0.76	0.37	-0.45	-0.93	-0.55	-0.75	-0.59	0.61	-0.54	0.99	0.61	-0.58	-0.55		-0.8	0.99	-0.67	-0.96	-0.96
Capital Surpluse	0.9	0.93	0.88	-0.3	0.36	0.84	0.75	0.87	0.88	-0.75	0.85	-0.72	-0.85	0.71	0.68	-0.8		-0.72	0.93	0.85	0.85
Deferred Long Term Liab	-0.51	-0.78	-0.68	0.38	-0.48	-0.92	-0.47	-0.66	-0.49	0.52	-0.42	1.0	0.51	-0.49	-0.46	0.99	-0.72		-0.59	-0.95	-0.95
Current Deferred Revenue	0.88	0.91	0.84	-0.27	0.42	0.75	0.69	0.81	0.86	-0.67	0.85	-0.59	-0.81	0.63	0.63	-0.67	0.93	-0.59		0.72	0.72
Short Long Term Debt	0.63	0.82	0.71	-0.41	0.51	0.97	0.55	0.7	0.6	-0.55	0.51	-0.95	-0.59	0.51	0.47	-0.96	0.85	-0.95	0.72		1.0
Short Term Debt	0.63	0.82	0.71	-0.41	0.51	0.97	0.55	0.7	0.6	-0.55	0.51	-0.95	-0.59	0.51	0.47	-0.96	0.85	-0.95	0.72	1.0

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Harmony Biosciences

Working Capital Over Time

Harmony Net Invested Capital

Net Invested Capital

693.59 Million

At this time, Harmony Biosciences' Net Invested Capital is fairly stable compared to the past year.

According to the company's disclosures, Harmony Biosciences Holdings has a Working Capital of 287.29 M. This is 32.51% lower than that of the Pharmaceuticals sector and 46.66% lower than that of the Health Care industry. The working capital for all United States stocks is 80.56% higher than that of the company.

Harmony Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Harmony Biosciences' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Harmony Biosciences could also be used in its relative valuation, which is a method of valuing Harmony Biosciences by comparing valuation metrics of similar companies.

Harmony Biosciences is currently under evaluation in working capital category among its peers.

Harmony Biosciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of Harmony Biosciences from analyzing Harmony Biosciences' financial statements. These drivers represent accounts that assess Harmony Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Harmony Biosciences' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	2.4B	2.1B	2.5B	3.3B	1.9B	1.8B
Enterprise Value	2.4B	2.0B	2.4B	3.2B	1.8B	1.9B

Harmony Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Harmony Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Harmony Biosciences' managers, analysts, and investors.

Environmental

Governance

Social

Harmony Fundamentals

	Return On Equity	0.23
	Return On Asset	0.13
	Profit Margin	0.18 %
	Operating Margin	0.33 %
	Current Valuation	1.75 B
	Shares Outstanding	57.03 M
	Shares Owned By Insiders	11.62 %
	Shares Owned By Institutions	92.86 %
	Number Of Shares Shorted	5.8 M
	Price To Earning	293.37 X
	Price To Book	3.31 X
	Price To Sales	2.99 X
	Revenue	582.02 M
	Gross Profit	354.37 M
	EBITDA	221.51 M
	Net Income	128.85 M
	Cash And Equivalents	254.17 M
	Cash Per Share	4.30 X
	Total Debt	193.57 M
	Debt To Equity	0.79 %
	Current Ratio	4.91 X
	Book Value Per Share	10.46 X
	Cash Flow From Operations	219.39 M
	Short Ratio	5.15 X
	Earnings Per Share	2.11 X
	Target Price	47.11
	Number Of Employees	246
	Beta	0.77
	Market Capitalization	2.04 B
	Total Asset	811.45 M
	Retained Earnings	(143.28 M)
	Working Capital	287.29 M
	Net Asset	811.45 M

About Harmony Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Harmony Biosciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harmony Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harmony Biosciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Harmony Stock Analysis

When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC